Cullinan Therapeutics (CGEM) Income towards Parent Company (2021 - 2023)
Historic Income towards Parent Company for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to -$25.6 million.
- Cullinan Therapeutics' Income towards Parent Company rose 555.66% to -$25.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$155.1 million, marking a year-over-year decrease of 24197.15%. This contributed to the annual value of -$167.6 million for FY2024, which is 804.25% down from last year.
- Latest data reveals that Cullinan Therapeutics reported Income towards Parent Company of -$25.6 million as of Q4 2023, which was up 555.66% from -$39.2 million recorded in Q3 2023.
- In the past 5 years, Cullinan Therapeutics' Income towards Parent Company registered a high of $174.1 million during Q2 2022, and its lowest value of -$58.1 million during Q1 2023.
- Moreover, its 3-year median value for Income towards Parent Company was -$25.2 million (2022), whereas its average is -$9.4 million.
- The largest annual percentage gain for Cullinan Therapeutics' Income towards Parent Company in the last 5 years was 115885.39% (2022), contrasted with its biggest fall of 100627.2% (2022).
- Over the past 3 years, Cullinan Therapeutics' Income towards Parent Company (Quarter) stood at -$34.2 million in 2021, then increased by 20.87% to -$27.1 million in 2022, then grew by 5.56% to -$25.6 million in 2023.
- Its Income towards Parent Company was -$25.6 million in Q4 2023, compared to -$39.2 million in Q3 2023 and -$32.2 million in Q2 2023.